Brief: Beijing Biostar Pharmaceuticals Announces Approval Of Utidelone Capsule By U.S. FDA
05/02/2025 14:57
Feb 5 (Reuters) - Beijing Biostar Pharmaceuticals Co Ltd
2563.HK :
* APPROVAL OF UTIDELONE CAPSULE IN PHASE II/III
INTERNATIONAL
MULTI-CENTER CLINICAL STUDY BY U.S. FDA
Further company coverage: 2563.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beijing Biostar Pharmaceuticals
See all newsBrief: Beijing Biostar Pharmaceuticals To Issue 25 MLN New Shares At HK$4.00 Per Share
Brief: Beijing Biostar Pharmaceuticals Says Board Resolves To Repurchase H Shares In Open Market
Brief: Beijing Biostar Pharmaceuticals Posts FY Loss Attributable RMB131.4 Mln
Brief: FDA Grants Orphan Drug Designation To Biostar Pharma's Utidelone
Brief: Biostar Pharma Doses First Patients In Two Phase II/III Global Trials Of Utidelone Capsule (UTD2) For Cancer